Newswire (Published: Tuesday, June 6, 2017, Received: Thursday, June 1, 2017, 3:13:06 PM CDT)

Word Count: 490

New Prostate Cancer Findings from University of California Reported (Impact of the United States Preventive Services Task Force 'D' recommendation on prostate cancer screening and staging)

By a News Reporter-Staff News Editor at Cancer Weekly -- New research on Oncology - Prostate Cancer is the subject of a report. According to news reporting out of San Francisco, California, by NewsRx editors, research stated, "In 2012, the United States Preventive Services Task Force (USPSTF) issued a grade 'D' recommendation against the use of routine prostate-specific antigen (PSA)-based screening for any men. This recommendation reflects critical misinterpretations of the available evidence base regarding benefits and harms of PSA screening and has influenced the nationwide landscape of prostate cancer screening, diagnosis, and treatment."

Our news journalists obtained a quote from the research from the University of California, "Following the USPSTF recommendation, a substantial decline in PSA screening was noted for all age groups. Similarly, overall rates of prostate biopsy and prostate cancer incidence have significantly decreased with a shift toward higher grade and stage disease upon diagnosis. Concurrently, the incidence of metastatic prostate cancer has significantly risen in the United States. These trends are concerning particularly for the younger men with occult high-grade disease who are expected to benefit the most from early detection and definitive prostate cancer treatment. These emerging trends in PSA screening and prostate cancer incidence following the USPSTF recommendation may have significant public health implications. Due to the long natural history of the disease, a long-term follow-up is needed to provide a better understanding on the implications of such recommendations on disease progression and mortality rates in prostate cancer patients."

According to the news editors, the research concluded: "The future of US screening policy should reflect a targeted 'smarter' screening strategy rather than dichotomizing the decision between 'screen all' or 'screen none."

For more information on this research see: Impact of the United States Preventive Services Task Force 'D' recommendation on prostate cancer screening and staging. Current Opinion in Urology, 2017;27(3):205-209. Current Opinion in Urology can be contacted at: Lippincott Williams & Wilkins, Two Commerce Sq, 2001 Market St, Philadelphia, PA 19103, USA. (Lippincott Williams and Wilkins - www.lww.com; Current Opinion in Urology - journals.lww.com/co-urology/pages/default.aspx)

Our news journalists report that additional information may be obtained by contacting M.R. Cooperberg, University of California, Dept. of Epidemiol & Biostat, Helen Diller Family Comprehens Canc Center, San Francisco, CA 94143, United States. Additional authors for this research include A. Herlemann, S.L. Washington and R.S. Eapen (see also Oncology - Prostate Cancer).

Keywords for this news article include: San Francisco, California, United States, North and Central America, Cancer, Article Review, Diagnostics and Screening, Prostate-Specific Antigen, Enzymes and Coenzymes, Prostatic Neoplasms, Prostate Cancer, Oncology, University of California.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

Companies

University of California
Lippincott Williams & Wilkins
Wolters Kluwer N.V.
Wolters Kluwer N.V.
Wolters Kluwer N.V.

Places

Central America
North America
United States
Americas
California
Pennsylvania
Washington
San Francisco
Philadelphia

Subjects

Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
            Urological Diseases
      Medical Specialties and Practices
            Urology